Pharma BD Deal Intelligence
A $2.1B bet on an unapproved radioligand asset that became Pluvicto, a $2B/year blockbuster anchoring Novartis's radioligand platform. The FDA's March 2025 label expansion to pre-taxane mCRPC roughly tripled the eligible patient population, though a 2023 manufacturing shortage briefly halted new patient starts.
The $2.1B bet on an unapproved radioligand became Pluvicto, a $2B/yr (and rising toward $5B by 2030) blockbuster and the anchor of Novartis's radioligand therapy platform.
Full analysis, sources & comparables →Novartis acquired Endocyte for $2.1B for 177Lu-PSMA-617 radiopharmaceutical candidate.
VISION Phase 3 trial showed 177Lu-PSMA-617 plus standard care extended OS by 4.0 months (HR 0.62) versus standard care alone in mCRPC — landmark data…
Acquirer SEC 6-K (Tier 2); Pluvicto FY2025 net sales USD 605M, +70% cc — validates the radioligand-platform acquisition thesis.
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Novartis announced October 2018 acquisition of Indiana-based Endocyte for $24/share cash, total equity value $2.1B. Adds Phase 3 177Lu-PSMA-617 (later Pluvicto), a first-in-class PSMA-targeted radioligand therapy for mCRPC, plus preclinical 225Ac-PSMA-617. Builds on Novartis's January 2018 AAA acquisition (Lutathera) to consolidate radiopharmaceuticals leadership. Closed December 21, 2018; Pluvicto won initial FDA approval in post-taxane mCRPC in March 2022. The acquisition thesis has since strengthened: on March 28, 2025 the FDA approved Pluvicto for earlier, pre-taxane use in PSMA-positive mCRPC (PSMAfore trial: 59% reduction in risk of radiographic progression/death; rPFS 11.6 vs 5.6 months), roughly tripling the eligible patient population. On June 2, 2025 the Phase 3 PSMAddition trial met its primary rPFS endpoint in metastatic hormone-sensitive prostate cancer (HR 0.72) with a regulatory submission planned. Pluvicto generated USD 605M in FY2025 net sales (+70% cc), confirming the radioligand-platform bet behind the Endocyte deal.
The $2.1B bet on an unapproved radioligand became Pluvicto, a $2B/yr (and rising toward $5B by 2030) blockbuster and the anchor of Novartis's radioligand therapy platform.
Assessment window: 5yr post-close.
45K US cases/yr · $12.0B Global mCRPC therapeutics
mCRPC is advanced prostate cancer that progressed despite androgen deprivation. Novel hormonal agents, PARP inhibitors, and radioligand therapy (Lu-177 PSMA-617) have expanded options.
AR-targeted agents (enzalutamide, abiraterone), taxane chemo, PARP inhibitors (olaparib for HRR-mutated), Lu-177 PSMA-617 (Pluvicto). Key players: Pfizer/Astellas (Xtandi), J&J (Zytiga), Novartis (Pluvicto), AZ (Lynparza).
43K US cases/yr · $2.0B Pluvicto peak sales analyst expectation (FiercePharma 2022)
Metastatic castration-resistant prostate cancer (mCRPC) is advanced prostate cancer that progresses despite androgen deprivation therapy, with US prevalence estimated at ~43,000 men in 2020 and rising as patients live longer on novel hormonal agents. Median survival historically ranged 2-3 years, and the disease is diagnosed predominantly in men over 70 with bone (65%) and lymph node (15%) metastases as the most common first sites.
When Novartis announced the $2.1B Endocyte acquisition in October 2018, the post-chemotherapy mCRPC space was dominated by Xtandi (enzalutamide, Pfizer/Astellas), Zytiga (abiraterone, J&J), Jevtana (cabazitaxel, Sanofi), and Xofigo (radium-223, Bayer) — Novartis had no presence. 177Lu-PSMA-617 offered a precision-targeted radioligand mechanism delivering beta-particle radiation to PSMA-expressing tumor cells, with Phase 2 data already showing PSA responses in chemo-refractory patients. The deal layered onto Novartis's January 2018 $3.9B AAA acquisition that brought Lutathera in neuroendocrine tumors, signaling deliberate radiopharmaceutical platform-building. The thesis paid off: the VISION Phase 3 trial published in NEJM (June 2021) showed a 4.0-month OS benefit and 38% mortality risk reduction; FDA approved Pluvicto on March 23, 2022 as the first targeted radioligand therapy for PSMA-positive mCRPC. Novartis subsequently filed for an earlier-line indication (PSMAfore trial, pre-chemotherapy mCRPC), approved in 2025. Pluvicto has become a multibillion-dollar franchise — Novartis reported it as one of its fastest-growing brands by 2024 — vindicating the original $2.1B all-cash thesis. Competing PSMA-targeted radioligands from Lantheus/POINT (PNT2002), Curium, and Telix are in late-stage development but Pluvicto retains first-to-market advantage and manufacturing scale.
Novartis completed $2.1B acquisition of Endocyte, gaining 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer.
FDA approved Pluvicto for PSMA-positive mCRPC, first PSMA-targeted radioligand therapy and anchor of Novartis's radiopharmaceutical franchise.
Pluvicto generated $1.39B in 2024 (42% growth YoY), well exceeding $2.1B acquisition cost. Novartis established as radiopharmaceutical leader.
$1.39B annual revenue by 2024, >60% ROI within 2 years of launch. First-line expansion could push peak sales past $5B. Best pharma acquisition of the decade.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Endocyte, Inc. (this deal) | 2018 | $2.1B | 96 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2018 deals · Novartis AG deals · Oncology deals